| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $106,321,727 | 35 | 100 |
| Cole G Bradley | director | 0 | $0 | 1 | $299,092 | $-299,092 |
| Tessari Eben | CHIEF OPERATING OFFICER | 0 | $0 | 3 | $1.02M | $-1.02M |
| Quart Barry D | director | 0 | $0 | 7 | $2.68M | $-2.68M |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | 0 | $0 | 3 | $4.1M | $-4.1M |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | 0 | $0 | 6 | $8.94M | $-8.94M |
| Moat Ross | CHIEF OPERATING OFFICER | 0 | $0 | 4 | $9.82M | $-9.82M |
| Paolini John F. | CHIEF MEDICAL OFFICER | 0 | $0 | 4 | $13.87M | $-13.87M |
| Patel Sanj K | CHAIRMAN & CEO | 0 | $0 | 7 | $65.59M | $-65.59M |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent …
Over the last 12 months, insiders at Kiniksa Pharmaceuticals International, plc have bought $0 and sold $106.32M worth of Kiniksa Pharmaceuticals International, plc stock.
On average, over the past 5 years, insiders at Kiniksa Pharmaceuticals International, plc have bought $0 and sold $44.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,686,704 shares for transaction amount of $31.99M was made by Flynn James E (10 percent owner) on 2018‑05‑29.
| 2026-11-03 | Sale | Patel Sanj K | CHAIRMAN & CEO | 220,170 0.2802% | $93.27 | $20.54M | +0.02% | |
| 2026-11-02 | Sale | Patel Sanj K | CHAIRMAN & CEO | 89,433 0.1157% | $91.86 | $8.22M | +1.56% | |
| 2026-11-02 | Sale | Paolini John F. | CHIEF MEDICAL OFFICER | 18,413 0.0242% | $93.39 | $1.72M | -0.11% | |
| 2026-11-02 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 36,783 0.0477% | $92.16 | $3.39M | +1.22% | |
| 2026-11-02 | Sale | Moat Ross | CHIEF OPERATING OFFICER | 27,977 0.0364% | $92.36 | $2.58M | +1.00% | |
| 2026-10-30 | Sale | Patel Sanj K | CHAIRMAN & CEO | 92,891 0.1199% | $93.12 | $8.65M | ||
| 2026-10-30 | Sale | Paolini John F. | CHIEF MEDICAL OFFICER | 77,587 0.1001% | $93.02 | $7.22M | ||
| 2026-10-30 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 36,260 0.0475% | $94.43 | $3.42M | ||
| 2026-10-30 | Sale | Moat Ross | CHIEF OPERATING OFFICER | 75,608 0.0976% | $93.13 | $7.04M | ||
| 2026-09-03 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 4,600 0.006% | $80.30 | $369,380 | -3.09% | |
| 2026-07-29 | Sale | Cole G Bradley | director | 3,673 0.0048% | $81.43 | $299,092 | -3.44% | |
| 2026-05-01 | Sale | Paolini John F. | CHIEF MEDICAL OFFICER | 58,424 0.0765% | $53.71 | $3.14M | +36.03% | |
| 2026-05-01 | Sale | Patel Sanj K | CHAIRMAN & CEO | 48,565 0.0667% | $54.02 | $2.62M | +36.03% | |
| 2026-04-30 | Sale | Patel Sanj K | CHAIRMAN & CEO | 2,141 0.0029% | $54.01 | $115,635 | +39.74% | |
| 2026-04-28 | Sale | Quart Barry D | director | 13,099 0.0164% | $50.10 | $656,260 | +39.42% | |
| 2026-04-28 | Sale | Patel Sanj K | CHAIRMAN & CEO | 483,654 0.6277% | $51.86 | $25.08M | +39.42% | |
| 2026-04-09 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 6,625 0.0085% | $46.69 | $309,321 | +37.48% | |
| 2026-04-09 | Sale | Moat Ross | CHIEF OPERATING OFFICER | 1,703 0.0022% | $46.69 | $79,513 | +37.48% | |
| 2026-04-06 | Sale | Quart Barry D | director | 6,901 0.0094% | $50.00 | $345,050 | +30.23% | |
| 2026-04-06 | Sale | Moat Ross | CHIEF OPERATING OFFICER | 2,367 0.0031% | $48.58 | $114,989 | +30.23% |
| Patel Sanj K | CHAIRMAN & CEO | 780037 0.9928% | $72.77M | 1 | 28 | |
| BAKER BROS. ADVISORS LP | 2700597 3.4371% | $251.94M | 2 | 0 | +4.3% | |
| Cormorant Asset Management, LP | director | 900443 1.146% | $84M | 1 | 0 | +4.3% |
| Flynn James E | 10 percent owner | 843352 1.0734% | $78.68M | 1 | 0 | +4.3% |
| Beetham Thomas W. | EVP & Chief Legal Officer | 297523 0.3787% | $27.76M | 1 | 6 | |
| BOESS CARSTEN | 10 percent owner | 6392 0.0081% | $596,309.68 | 1 | 0 | |
| Heberlig Chris | Exec VP & CFO | 6392 0.0081% | $596,309.68 | 1 | 0 | |
| Mahoney Stephen F. | President & COO | 6392 0.0081% | $596,309.68 | 1 | 0 |
| Increased Positions | 125 | +57.08% | 14M | +33.53% |
| Decreased Positions | 93 | -42.47% | 4M | -10.5% |
| New Positions | 45 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 412,952 | Sold Out |
| Total Postitions | 251 | +14.61% | 51M | +23.02% |
| Rubric Capital Management Lp | $168,020.00 | 8.89% | 4M | +90,194 | +2.31% | 2025-09-30 |
| Vanguard Group Inc | $128,667.00 | 6.81% | 3.06M | -68,467 | -2.19% | 2025-09-30 |
| Baker Bros. Advisors Lp | $118,650.00 | 6.28% | 2.82M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $97,813.00 | 5.18% | 2.33M | 0 | 0% | 2025-09-30 |
| Fairmount Funds Management Llc | $74,468.00 | 3.94% | 1.77M | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $67,986.00 | 3.6% | 1.62M | +350,532 | +27.64% | 2025-09-30 |
| Morgan Stanley | $57,250.00 | 3.03% | 1.36M | +296,644 | +27.82% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $47,641.00 | 2.52% | 1.13M | +342,881 | +43.33% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $44,872.00 | 2.37% | 1.07M | +332,846 | +45.26% | 2025-09-30 |
| Millennium Management Llc | $42,598.00 | 2.25% | 1.01M | -5,843 | -0.57% | 2025-09-30 |